Future investigations should now focus on the identification and functional evaluation of YB-1 transcriptional targets involved in the re-sensitisation as well as of further mediators of RSK signalling, such as the inactivated pro-apoptotic Bad, to fully elucidate the molecular mechanism behind the detrimental effect of RSK inhibitors on MAPK inhibitor resistant melanoma cells. Here, YBX1 is linked to melanoma.